Definium's LSD Pill Posts Second Positive Phase 3 Result in Anxiety, Nears FDA Filing
- Definium Therapeutics reported positive topline results from its Phase 3 "Panorama" study of DT120, an orally-dissolving LSD tablet, in adults with generalized anxiety disorder.
- The trial met its primary and key secondary endpoints, with the drug arm showing roughly a 5-point greater reduction in Hamilton Anxiety Rating Scale scores than placebo over 12 weeks.
- This marks the second of two pivotal Phase 3 anxiety trials to read out positively this year, following August's "Voyage" study, and the third positive Phase 3 result overall for DT120 across its anxiety and depression programs.
- Definium said it now plans to submit a new drug application to the FDA in the first half of 2027, placing it among the first psychedelic-therapy developers nearing US approval.
"Among the first" matters less than what Lykos's 2024 rejection taught this field: FDA's psychedelic bar is procedural — blinding integrity, therapist-assisted dosing, abuse-liability and REMS design — not just topline efficacy. Definium has now proven the molecule three times over; it hasn't yet proven it solves the trial-design problem that sank MAPS. Compass Pathways is still fighting depression with psilocybin, MindMed trails on Phase 3 timing — Definium's 2/2 in anxiety and 3/3 overall looks like a real platform effect, not a lucky readout, and that replication is the sharper differentiator than filing order. GAD's addressable population dwarfs the PTSD and treatment-resistant-depression pools psychedelics have chased; the market upside here is genuinely bigger than prior programs, but only if in-clinic monitoring costs don't eat the model. Net effect: this de-risks the pharmacology for the whole psychedelic class more than it de-risks Definium's commercial path — REMS and administration burden, not another efficacy win, are now the swing factor for 2027.
Definium's LSD therapy shows positive effect on anxiety in trial ↗